Reduction in pain with etoricoxib use in patients with osteoarthritis

Summaries 3 min 327

Font Size

Created On: 15/07/2022

An open observational study aimed to assess the influence of etoricoxib on signs of central sensitization (CS) and pain in osteoarthritis patients.

See All

Key take away

In osteoarthritis people, etoricoxib was associated with pain improvement and reduction in severity of signs of central sensitization.

Background

An open observational study aimed to assess the influence of etoricoxib on signs of central sensitization (CS) and pain in osteoarthritis patients.

Method

Overall, 790 subjects with a mean age of 54.5 ± 13.0 years suffering from osteoarthritis (hip or knee) were incorporated. For two weeks, all the subjects were given etoricoxib 60 mg/day. Utilizing a numerical rating scale (NRS 0-10), an assessment of the dynamics of pain was done. Utilizing Central Sensitization Inventory (CSI), evaluation of dynamics of CS signs was done. CSI ≥40 was seen in 35.3% of subjects.

Result

The intensity of pain at movement, at rest and at night lowered following 2 weeks of intervention with etoricoxib, as depicted in Table 1:

A reduction in CSI values by 33.1±14.5% was seen. Additionally, the number of subjects with CSI ≥40 decreased from 35.3% to 10.3%. No major complications were observed during the intervention. Notably, 5.9% of side effects, majorly arterial hypertension and dyspepsia were witnessed.

Conclusion

The non-steroidal anti-inflammatory drug (NSAID) etoricoxib reduced the severity of CS symptoms and pain in osteoarthritis patients, confirming the drug's key mechanism of action.